IL6 and hepatocellular carcinoma: As an anti-cancer agent, ligustilide can reduce expression level and nuclear transfer of YAP to suppress IL-6 secretion in impairing M2 polarization and shifting macrophage polarization to M1 in decreasing HCC progression [200].